Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer

Non-small cell lung carcinoma (NSCLC) stage III accounts for 25-30% of all patients with NSCLC.[1] Patients with stage III NSCLC have frequently unresectable disease.[2] Concurrent chemoradiotherapy (cCRT) is the preferred non-surgical treatment for such patients, yet the best 5-year overall survival (OS) (32%) and progression free survival (PFS) (18%) reported in a phase III randomized controlled trial are disappointing.[3] The PACIFIC regimen is the paradigm establishing a survival benefit for adjuvant durvalumab, an anti —PD-L1 antibody after cCRT.

Source: Radiotherapy and Oncology - February 8, 2024 Category: Radiology Authors: I. Smesseim, O.M. Mets, J.M.A. Daniels, I. Bahce, S. Senan Tags: Original Article Source Type: research